ANTIHISTAMINES ARE widely used to treat allergic. Desloratadine Shows No Effect on Performance During 6 h at 8,000 ft Simulated Cabin Altitude
|
|
- Fay Andrea Dorsey
- 5 years ago
- Views:
Transcription
1 RESEARCH ARTICLE Desloratadine Shows No Effect on Performance During 6 h at 8,000 ft Simulated Cabin Altitude Pierre J. L. Valk, Dominique B. Van Roon, Ries M. Simons, and Ger Rikken VALK PJL, VAN ROON DB, SIMONS RM, RIKKEN G. Desloratadine shows no effect on performance during 6hat8,000 ft simulated cabin altitude. Aviat Space Environ Med 2004; 75: Introduction: Sustained vigilance is required by pilots and crew during flight; therefore, the use of antihistamines with sedating properties is widely prohibited. The purpose of this study was to determine the effects of desloratadine, a long-acting, nonsedating antihistamine, on healthy volunteers placed under conditions of simulated cabin pressure. Methods: In a double-blind crossover study, 21 subjects randomly received single doses of desloratadine 5 mg, diphenhydramine 50 mg (active control), and placebo on different days separated by washout periods of 7 d. On test days, predose levels of alertness and fatigue were determined, as were post-dose levels at 1, 2, 3, 5, and 6 h. Measurements included vigilance and tracking, a multi-attribute task battery, the Stanford Sleepiness Scale, and pulse oximetry. Results: Desloratadine had no detrimental effects on sleepiness or performance of tasks associated with flying ability. Conversely, diphenhydramine (active control) caused significantly more sleepiness than did the placebo [F (2,40) 6.52, p 0.01], as well as impaired performance (tracking performance p 0.05 at 3 h post dose), and an increased percentage of omissions (p 0.05 at 2 h post dose). Conclusion: A single dose of desloratadine 5 mg did not cause sleepiness and did not impair the performance of tasks associated with flying ability. Keywords: aviation, cognitive performance, H 1 -receptor antagonist, desloratadine. ANTIHISTAMINES ARE widely used to treat allergic rhinitis (AR), but many of these agents cause sedation and have been shown to impair in-flight performance (10,19). Pilots may be particularly vulnerable to the sedative effects of antihistamines because they are required to sustain attention and vigilance under relatively monotonous conditions (18,26). Other crewmembers, such as navigators, tactical crew, and air traffic controllers, must also maintain vigilance and are, therefore, also vulnerable to the sedating effects of antihistamines. It is not surprising that the use of antihistamines with sedative properties in crew during flight is widely prohibited. Desloratadine is a long-acting, peripheral H 1 -receptor antagonist with antiallergic, anti-inflammatory, and decongestant activity (9). In clinical trials, desloratadine has been shown to relieve the nasal and nonnasal symptoms of seasonal AR (22), including nasal congestion (16), as well as the symptoms of asthma in patients with AR and concomitant asthma (2), and the symptoms of chronic idiopathic urticaria (21). In clinical trials, desloratadine has demonstrated an adverse event profile similar to that of placebo (9,21). The objective of this Aviation, Space, and Environmental Medicine Vol. 75, No. 5 May 2004 study was to determine the effects of desloratadine on sleepiness and performance (vigilance, tracking, communicating, and managing resources) in healthy volunteers placed under conditions of simulated cabin pressure. METHODS Study Design/Medication This was a randomized, double-blind, placebo-controlled, single-center crossover study. A computer-generated randomization schedule was used to randomly assign doses of desloratadine 5 mg, diphenhydramine 50 mg (active control), and placebo to qualifying subjects. Each dose of study drug was administered orally in the morning with 200 ml of water at approximately the same time each day (9:30 a.m.). All subjects received all three treatments with at least a 7-d washout period between treatment phases. Use of caffeine-containing products was prohibited on the day of testing and was limited to three portions on the day before testing. Subjects Healthy male subjects between the ages of 18 and 40 were considered for inclusion. All subjects were nonsmokers, had a negative urine screen for drug abuse, and were free of clinically significant disease. Previous flight/hypobaric experience was not required. Results of standard laboratory biochemistry, hematology, and urinalysis tests obtained at screening were within normal limits. All included subjects displayed an adequate adaptation toward the differences in cabin pressure and were able to complete the tests adequately. An institutional review board approved the study protocol, and From the TNO Human Factors Research Institute, Soesterberg, The Netherlands (P. J. L. Valk, R. M. Simons), NICI, University of Nijmegen, The Netherlands (D. B. van Roon), and the Schering-Plough Research Institute, Kenilworth, NJ (G. Rikken). This manuscript was received for review in July It was revised in December It was accepted for publication in December Address reprint requests to: P. J. L. Valk, TNO Human Factors Research Institute, Work Environment/Aviation Medicine Group, P.O. Box 23, 3769 ZG Soesterberg, The Netherlands; valk@tm.tno.nl. Reprint & Copyright by Aerospace Medical Association, Alexandria, VA. 433
2 all subjects signed consent forms after being thoroughly informed about the study and study medications. Subjects were excluded if they had active seasonal and/or perennial allergic rhinitis; had a history of allergies to more than two classes of medication; were allergic to or could not tolerate antihistamines; had a condition that might impair the absorption, metabolism, or excretion of desloratadine or diphenhydramine; had an upper respiratory tract infection, sinus infection, or viral upper respiratory infection within 7 d before screening; or were not within 10% of normal average body weight. Additional exclusion criteria included use during the study of any central nervous system medication or medications with sedative effects; use of an investigational drug within 1 mo before the screening visit; use of a sedative/hypnotic, antihistamine, or anticholinergic drug during the 2 wk before the first treatment phase; and consumption of alcoholic beverages within 24 h before the start of the study or during treatment study days. Study Procedures At a screening visit, the eligibility of subjects and their vital signs were assessed, a medical history and physical examination were conducted, and laboratory tests and an electrocardiogram were performed. On the same day, subjects were trained on the performance tests several times until a stable performance level was achieved. An ear sinus check was completed in the hypobaric chamber to familiarize subjects with the decrease and increase in cabin pressure. On study days, 1 h before treatment, subjects completed the Groningen Sleep Quality Scale (GSQS) to provide information on the quality of their sleep during the night before the trial day. Subjects with a bad night s sleep were rescheduled. Subjects were placed in a hypobaric chamber; over a period of 15 min, the ambient pressure in the hypobaric chamber was decreased to a pressure of 564 mmhg (75 kpa), equivalent to 2,438 m in the Standard Atmospheric. This pressure was chosen to represent pressurized cabins, which are normally maintained in the range of m ( ft) during cruising flight. The Vigilance and Tracking Test (VigTrack), the Multi-Attribute Task Battery (MAT), the Stanford Sleepiness Scale (SSS), and pulse oximetry were performed after this level of ambient pressure was reached. Study drug was administered following completion of these assessments. VigTrack, MAT, SSS, and pulse oximetry were also performed 1, 2, 3, 5, and 6 h after administration of the study treatment. Physical exercise was prohibited while subjects were in the hypobaric chamber, but activities (including playing games, reading magazines and books, and participating in active discussions) were provided so that daytime somnolence could be avoided. At the end of the study, ambient pressure was increased to that of sea level (simulating descent), and subjects were discharged to their homes after they had been medically evaluated. Adverse events, which were monitored throughout the study, included those that were spontaneously reported, as well as those revealed through answers to general questioning and/or results of laboratory tests. VigTrack, MAT, and SSS are used in aviation research to determine pilot alertness and fatigue. VigTrack is an instrument that measures vigilance performance under the continuous load of a compensatory tracking task that is used in field studies to assess the effects of fatigue and sleepiness in pilots (27,28). The task was developed on a Psion 3a palmtop computer. With arrow keys and a response button, subjects simultaneously track and respond to movement on a computer display. Data are gathered on tracking and vigilance performance. MAT provides a benchmark set of tasks for use in a wide range of laboratory studies of operator performance and workload (1,6). This battery incorporates tasks analogous to activities that aircraft crewmembers perform in flight, and it provides a high degree of experimenter control and performance data on each subtask. Features include a system monitoring task, a tracking task, a communications task, and a resource management task, all of which are performed simultaneously. Performance measurements include the following: 1) root mean squared (RMS) tracking error; 2) numbers of false reactions and omissions, as well as mean reaction time; 3) numbers of adequate responses, false reactions, and omissions, as well as decision and response times; and 4) RMS deviation from fuel level target. The SSS is a subjective rating scale used to assess sleepiness (12). Scale measures have been highly correlated with flying performance and threshold of information processing speed during periods of intense fatigue (18). The SSS consists of seven statements (ranging from feeling active and vital to sleep onset soon ); subjects indicate how they feel at the moment by indicating which description best fits their condition. The GSQS consists of 14 different sleep quality statements; subjects must determine which statements are applicable to their sleep during the previous night (15). A score of 6 points or greater reflects a bad night s sleep. The peripheral hemoglobin-oxygen saturation (SaO 2 ) value in the peripheral blood of each subject was determined with the use of a pulse oximeter with a finger clip sensor. The SaO 2 of subjects staying at a simulated altitude of 8,000 ft has been shown to range from 89% to 93% (25). This mild hypoxia has been associated with performance impairment in some studies (25); however, others suggest that greater hypoxia (e.g., that experienced at 10,000 ft) is necessary to produce detectable performance impairment (25). Data Analysis To compensate for differences at baseline, difference scores were computed for all subjects during all three treatments by subtracting baseline scores from scores obtained in the five test sessions (1, 2, 3, 5, and 6 h post dose). Repeated measures of analysis of variance (ANOVA) were used to assess changes from baseline in VigTrack, MAT, SSS, and SaO 2 values. Within-subject factors included treatment and time of day. Comparisons between treatment at different time points were 434 Aviation, Space, and Environmental Medicine Vol. 75, No. 5 May 2004
3 Fig. 1. Effects of desloratadine 5 mg, diphenhydramine 50 mg, and placebo on tracking performance as measured on the VigTrack. RMS root mean squared. *p 0.01 vs. diphenhydramine; p vs. placebo; p vs. diphenhydramine; p 0.01 vs. placebo; ** p 0.05 vs. placebo. Desloratadine showed no significant difference vs. placebo at any time point. performed using Tukey s Honest Significant Difference method. Differences in SSS and GSQS scores were tested by means of the Wilcoxon matched-pairs signedrank test. The significance level was set at RESULTS A total of 21 healthy white men received all 3 treatments. The average age of the subjects was 22.6 yr; average weight and height were 73.4 kg and cm, respectively. No significant differences were noted among the three treatments with respect to subjective sleep quality during the night before the trial day, as determined according to the GSQS. A significant treatment session interaction was found [F (10,200) 5.20, p 0.001]. No significant differences were seen between desloratadine and placebo in tracking and vigilance as measured on VigTrack. Conversely, diphenhydramine impaired tracking performance (p 0.05 vs. placebo up to 3 h post dose). The diphenhydramine group showed impaired performance immediately following administration of the drug. This was followed by a linear improvement in performance at a level that was comparable with the desloratadine and placebo groups at the end of the day (Fig. 1). On tests of vigilance, no significant difference in the number of false reactions was observed between treatments; however, the treatment session interaction was significant [F (10,200) 3.16, p 0.001] and it was found that diphenhydramine produced a significant increase in the percentage of omissions vs. placebo (p 0.05 at 2 h post dose). The diphenhydramine group showed impaired performance immediately after administration of the drug. This was followed by a linear Aviation, Space, and Environmental Medicine Vol. 75, No. 5 May 2004 improvement in performance that reached a level comparable with that seen in the desloratadine and placebo groups at the end of the day (Fig. 2). On the subtask of tracking, a significant treatment session interaction was found [F (10,200) 3.86, p 0.001]. No significant differences in tracking performance between desloratadine and placebo as measured on MAT were noted at any time point. Diphenhydramine significantly impaired tracking performance early on (p at 1 h), at most time points throughout the study, and up to the final evaluation time point (6 h) compared with desloratadine and placebo. On the subtask of resource management, a significant session effect [F (5,100) 4.45, p 0.001] was found. The effect was similar for desloratadine and for placebo; each demonstrated overall improvement across the study period. In contrast, diphenhydramine produced significant impairment at the first assessment (p 0.05) compared with desloratadine; this also occurred after dosing over the duration of the study [F (1,20) 6.12, p 0.05] compared with placebo (Fig. 3). On the subtask of system monitoring, no significant differences were seen between groups in the number of omissions and the number of false reactions, and no significant difference in reaction time was observed between either of the antihistamines and placebo at any time point. However, regarding reaction time, a significant treatment session interaction was found [F (10,200) 1.91, p 0.05]. Reaction time in the desloratadine group was significantly shorter over the course of the study compared with diphenhydramine (p 0.01). On the subtask of communication, each group performed similarly with no significant differences in the 435
4 Fig. 2. Effects of desloratadine 5 mg, diphenhydramine 50 mg, and placebo on vigilance as measured on the VigTrack. * p 0.05 vs. diphenhydramine; p 0.01 vs. placebo; p 0.05 vs. placebo. Desloratadine showed no significant difference vs. placebo at any time point. number of adequate responses, number of omissions, number of false reactions, or response time. Daytime sleepiness measured with the SSS was comparable between desloratadine and placebo groups throughout the entire test period of 6 h. As was expected, diphenhydramine treatment was associated with a greater increase in sleepiness scores and significantly more sleepiness than was placebo [F (2,40) 6.52, p 0.01] (Fig. 4). No significant differences in SaO 2 values were seen between treatments. During the study, values remained at around 94% (range, 90% 98%) until ambient pressure was increased to that of sea level. No subjects in the placebo or desloratadine treatment groups reported any adverse events. There were three diphenhydramine-treated subjects who reported mild adverse events. Dizziness/wooziness, which occurred in one diphenhydramine-treated subject, was the only adverse event considered possibly related to a study drug; all other adverse events were considered unlikely to be related to a study drug. DISCUSSION The sedative properties of first-generation antihistamines are well recognized. Consequently, use of these agents in crewmembers during flight is generally prohibited. Compared with first-generation H 1 -receptor antagonists, second-generation antihistamines are larger and less lipophilic, and they have a higher affinity for protein binding. These agents are associated with lower penetration of the blood-brain barrier and, at therapeutic doses, are associated with less sedation than are first-generation antihistamines. Studies using the second-generation antihistamines fexofenadine (80 mg, 120 mg, and 180 mg) and loratadine (10 mg) have shown that neither cognitive function nor psychomotor function is impaired (5,11). However, some agents [e.g., cetirizine, levocetirizine (R-enantiomer of cetirizine)] have been shown to have a higher sedative potential than other second-generation antihistamines (13,20,23), although some recent studies of levocetirizine have not uncovered evidence of sedation (8,29). The literature describing the sedative potential of cetirizine and its R-enantiomer is inconsistent; this discrepancy may derive from shortcomings in the experimental design of some studies that do not allow assessment of the delayed effects of cetirizine (6 h or longer after dosing) on performance and sleepiness. The doses of desloratadine (5 mg) and diphenhydramine (50 mg) used in this study are consistent with those used to treat AR in clinical practice. Diphenhydramine can be administered at lower doses (25 mg); however, 50-mg doses have been employed in previous studies of flying task performance (5) and in a recent study of cognitive and psychomotor performance with repeated doses of various antihistamines (8). In addition to the sedating effects of antihistamines, the in-flight cabin pressure can affect flight performance (25). Lower ambient pressure in the cockpit during flight (range, kpa) has been associated with mild hypoxia (oxygen saturation of hemoglobin of 89 93%) and may result in impaired performance (7,14). Therefore, for accurate prediction of the true effect of treatment on crewmembers during flight, tests must be performed under conditions that mimic the in-flight 436 Aviation, Space, and Environmental Medicine Vol. 75, No. 5 May 2004
5 Fig. 3. Resource management scores at 1, 2, 3, 5, and 6 h after administration of desloratadine 5 mg, diphenhydramine 50 mg, and placebo as measured on the MAT. * p 0.05 vs. diphenhydramine; p 0.05 vs. placebo. Desloratadine showed no significant difference vs. placebo at any time point. environment. Although it was conducted in healthy volunteers, the present study was performed under conditions of simulated cabin pressure; therefore, it likely predicts the effects of desloratadine on performance and sleepiness in crewmembers during actual flight. As has been noted, this study was conducted in healthy male volunteers. We cannot predict if similar results would have been observed in women or in patients with AR. The results of this study are consistent with those of other clinical studies that assessed the effects of desloratadine on the central nervous system. Scharf and associates demonstrated that a single 7.5-mg dose of desloratadine did not impair wakefulness or psychomotor performance (24). Vuurman and colleagues demonstrated that a single 5-mg dose of desloratadine did not impair the driving performance of healthy volunteers (30). A recent report by Nicholson and colleagues (17) similarly found no adverse effects of desloratadine 5 mg on multiple measures of psychomotor performance, daytime sleep latencies, or subjective reports of sleepiness. The authors concluded that desloratadine could be suitable for persons involved in skilled activity and transport. No adverse events were observed with desloratadine Aviation, Space, and Environmental Medicine Vol. 75, No. 5 May 2004 treatment in this study. Previous single- and multipledose clinical studies have also demonstrated that desloratadine has a placebo-like adverse event profile (21). Unlike some other antihistamines, desloratadine is not associated with adverse cardiovascular effects (3,4). This study demonstrates that a single dose of desloratadine 5 mg has no detrimental effects on sleepiness Fig. 4. Effects of desloratadine 5 mg, diphenhydramine 50 mg, and placebo on sleepiness as measured by the SSS. * p 0.05 vs. placebo; p 0.01 vs. placebo; p 0.01 vs. diphenhydramine; p vs. placebo. Desloratadine showed no significant difference vs. placebo at any time point. 437
6 and performance of tasks associated with flying ability in healthy volunteers under conditions of simulated cabin pressure for up to 6 h after dosing. Conversely, the active control diphenhydramine is associated with significant sleepiness and impaired performance on flying tasks across this time period, confirming the sensitivity of the tests used. The results of this study indicate that after a single dose, desloratadine does not impair one s ability to process information, coordinate complex psychomotor tasks, or sustain attention and vigilance activities that are vital for maintenance of flight safety. Further studies are warranted to assess the effects on performance of multiple administrations of desloratadine. ACKNOWLEDGMENTS This study was supported by the Schering-Plough Research Institute, Kenilworth, NJ. REFERENCES 1. Arnegard RJ. Operator strategies under varying conditions of workload. Hampton, VA: Langley Research Center, NASA; Report No.: NASA CR Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 56(Suppl 65): Banfield C, Herron J, Keung A, et al. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 2002; 41(Suppl 1): Banfield C, Hunt T, Reyderman L, et al. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 2002; 41(Suppl 1): Bower EA, Moore JL, Moss M, et al. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med 2003; 74: Comstock AF, Arnegard RJ. The multi-attribute task battery for human operator workload and strategic behavior research. Hampton, VA: Langley Research Center, NASA; Report No.: NASA TM Denison DM, Ledwith F, Poulton EC. Complex reaction times at simulated cabin altitudes of 5,000 feet and 8,000 feet. Aerosp Med 1966; 37: Gandon JM, Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol 2002;54: Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107: Harding RM, Mills FJ. Is the crew fit to fly? II: Specific medical considerations. BMJ 1983; 287: Hindmarch I, Shamsi Z, Stanley N, Fairweather DB. A doubleblind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Pharmacol 1999; 48: Hoddes E, Zarcone V, Smythe H, et al. Quantification of sleepiness: A new approach. Psychophysiology 1973; 10: Howarth PH, Stern MA, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: Ledwith F. The effects of hypoxia on choice reaction time and movement time. Ergonomics 1970; 13: Meijman TF, DeVries GM, DeVries-Griever AHG, Kampman R. The evaluation of the Groningen sleep quality scale. Groningen, The Netherlands: Biological Centre, University of Groningen; Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56: Nicholson AN, Handford AD, Turner C, Stone BM. Studies on performance and sleepiness with the H 1 -antihistamine, desloratadine. Aviat Space Environ Med 2003; 74: Perelli LP. Fatigue stressors in simulated long-duration flight. Brooks AFB, TX: USAF School of Aerospace Medicine; Technical Report No.: Philpot EE, Brooker AE, Biegalski CS. Effects of sedating and nonsedating antihistamines on flying performance. Mil Med 1993; 158: Ramaekers JG, Uiterwijk MMC, O Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992; 42: Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study. Int J Dermatol 2001; 40: Salmun L, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [IS- RCTN ]. BMC Fam Pract 2002; 3: Salmun LM, Gates D, Scharf M, et al. Loratadine versus cetirizine: Assessment of somnolence and motivation during the workday. Clin Ther 2000; 22: Scharf MB, Kay G, Rikken G, et al. Desloratadine has no effect on wakefulness or psychomotor performance. Allergy 2000; 55(Suppl. 63): Simons M. Environmental factors influencing flight crew performance. In: Human factors digest no. 4. Proceedings of the ICAO Human Factors Seminar; 1990 Apr 3 7; Leningrad, USSR. Montreal: ICAO; 1990; Circular No.:229-AN/ Valk PJ, Simons RM, Struyvenberg PA, et al. Effects of a single dose of loratadine on flying ability under conditions of simulated cabin pressure. Am J Rhinol 1997; 11: Valk PJL. The assessment of vigilance under the continuous load of a compensatory tracking task. Soesterberg, The Netherlands: Netherlands Aerospace Medical Centre; Valk PJL, Simons M. Pros and cons of strategic napping on long haul flights. Neuilly-sur-Seine, France: NATO-AGARD; Report No.: AGARD-CP Verster JC, Volkerts ER, van Oosterwijck AW, et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003; 111: Vuurman E, Ramaekers JG, Rikken G, De Halleux F. Desloratadine does not impair actual driving performance: A 3-way crossover comparison with diphenhydramine and placebo. Allergy 2000; 55(Suppl. 63): Aviation, Space, and Environmental Medicine Vol. 75, No. 5 May 2004
Antihistamines are used as a first-line PROCEEDINGS THE VALUE OF A BROAD THERAPEUTIC INDEX FOR ANTIHISTAMINES * F. Estelle R. Simons, MD ABSTRACT
THE VALUE OF A BROAD THERAPEUTIC INDEX FOR ANTIHISTAMINES * F. Estelle R. Simons, MD ABSTRACT The therapeutic index of a histamine-1 (H 1 )- antihistamine is the benefit-to-risk ratio of the medication
More informationPOSTER PRESENTATIONS
POSTER PRESENTATIONS POSTER PRESENTATIONS The following are summaries of posters presented at the XXI Congress of the European Academy of Allergology and Clinical Immunology, Naples, Italy, June1-5, 2002.
More informationPEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the Children s Medical Center at the University of Virginia Volume 7 Number 4 April 2001 A The second-generation (peripherally-selective)
More informationMore than 6 decades have passed since
THE CONCEPT OF THE THERAPEUTIC WINDOW IN THE CHOICE OF H 1 -RECEPTOR ANTAGONIST * Peter H. Howarth, DM, FRCP ABSTRACT Antihistamines have existed for more than 60 years. The first-generation antihistamines
More informationMontelukast: a better alternative than antihistaminics in allergic rhinitis
International Journal of Otorhinolaryngology and Head and Neck Surgery Kaur G et al. Int J Otorhinolaryngol Head Neck Surg. 017 Apr;():17- http://www.ijorl.com pissn -99 eissn -97 Original Research Article
More informationMalaria Prophylaxis for Aircrew: Safety of Atovaquone/Proguanil in Healthy Volunteers under Aircraft Cabin Pressure Conditions
Malaria Prophylaxis for Aircrew: Safety of Atovaquone/Proguanil in Healthy Volunteers under Aircraft Cabin Pressure Conditions Ries Simons, Pierre J.L.Valk, and Arno J. Krul Background: Because malaria
More informationThe effects of antihistamines on cognition and performance
The effects of antihistamines on cognition and performance Gary G. Kay, PhD Washington, DC Allergic diseases are responsible for substantially more disability than is generally realized. Allergic rhinitis
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPRINCIPAL MEDICATION OPTIONS FOR RHINITIS
SEE INDICATED SUMMARY STATEMENT (SS#) DISCUSSION FOR SUPPORTING DATA ALLERGIC RHINITIS (AR): SEASONAL (SAR) AND PERENNIAL (PAR) MONOTHERAPY ORAL Antihistamines, oral (H1 receptor antagonists) (SS# 61-64)
More informationEfficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis
Human Journals Research Article July 2018 Vol.:10, Issue:1 All rights are reserved by Manju K Mathew et al. Efficacy of Levocetirizine Compared with Montelukast for the Treatment of Allergic Rhinitis Keywords:
More informationAbstract. Learning Objectives: 1. Even short duration of acute sleep deprivation can have a significant degradation of mental alertness.
Original Research Maintenance of Mental Alertness During Total Sleep Deprivation of Short Duration: A Double Blind, Placebo Controlled, Comparative Study Between Modafinil 100 mg and 200 mg Tripathy NK*,
More informationDaytime Sleepiness and Antihistamines
Sleep, 7(2): 137-141 1984 Raven Press, New York Daytime Sleepiness and Antihistamines imothy A. Roehrs, Elizabeth I. ietz, Frank J. Zorick, and homas Roth Sleep Disorders and Research Center, Henry Ford
More informationResearch Institute. Disclosures: Drs Danzig, Yao, and Staudinger are employees of Schering-Plough
A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber Friedrich Horak, MD* ; Petra Zieglmayer, MD*; René Zieglmayer, DI ; and
More informationPDF created with FinePrint pdffactory Pro trial version
Pilot Fatigue Pilot Fatigue Source: Aerospace Medical Association By Dr. Samuel Strauss Fatigue and flight operations Fatigue is a threat to aviation safety because of the impairments in alertness and
More informationAntihistamines: a brief review
Antihistamines: a brief review Van Schoor J, MPharm Amayeza Info Centre Introduction The prevalence rates of allergic diseases such as allergic rhinitis and asthma appear to be increasing in many countries.
More informationOpinion 8 January 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 8 January 2014 WYSTAMM 1 mg/ml, oral solution 120 ml vial with syringe for oral administration (CIP: 34009 222 560
More informationP Usharani, DNB, MD MUR Naidu, MD KLN Reddy, PhD * BPS Reddy, PhD * T Ramesh Kumar, MD
Randomized, Double-Blind, Crossover Comparison Between Two Levocetirizine Formulations on Histamine-Induced Cutaneous Response in Healthy Male Human Adult Volunteers P Usharani, DNB, MD MUR Naidu, MD KLN
More informationClinical Trial Synopsis TL , NCT#
Clinical Trial Synopsis, NCT#00492011 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ability of Ramelteon 1 mg, 4 mg, and 8 mg to Alleviate the Insomnia
More informationDoes Desloratadine Alter the Serum Levels of Montelukast When Administered in a Fixed-Dose Combination?
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Does Desloratadine Alter the Serum Levels of Montelukast When Administered in a Fixed-Dose Combination? Cemal
More informationData Collection Best Practices How to Manage Common Missteps
Data Collection Best Practices How to Manage Common Missteps Captain Brian Noyes, Member, Flight Time/Duty Time Committee, Air Line Pilots Association, Int l Captain Philip Otis, United Airlines Dr. Thomas
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationCLASSIFICATION OF SEDATING ANTIHISTAMINES
CLASSIFICATION OF SEDATING ANTIHISTAMINES TASK To examine the safety of sedating antihistamines and produce a report suggesting the most appropriate schedule for both combination and single ingredient
More informationEffects of acrivastine, loratadine and cetirizine on histamine-induced wheal and flare responses
Experimental dermatology Original article Effects of acrivastine, loratadine and cetirizine on histamine-induced wheal and flare responses D. Bayramgürler, N. Bilen, R. Apaydýn, L. Altıntaş,* G. Sal, Ş.
More informationDrug Review Rozerem (ramelteon)
Drug Review Rozerem (ramelteon) Introduction 1 Ramelteon is a melatonin receptor agonist with affinity for MT 1 and MT 2 and selectivity over the MT 3 receptor. The activity at the MT 1 and MT 2 receptors
More informationDYNAMIC INTERACTION OF NOMIFENSINE
Br. J. clin. Pharmac. (1977), 4, 147S-15 1S DYNAMIC INTERACTION OF NOMIFENSINE WITH ALCOHOL K. TAEUBER Medical Department, Hoechst AG, Postfach 8 3 2, D-623 Frankfurt/Main 8 1 Nine healthy volunteers participated
More informationClinical Medicine Reviews in Therapeutics. A Review of Rupatadine in the Treatment of Seasonal Allergic Rhinitis. R. Borici-Mazi.
Clinical Medicine Reviews in Therapeutics ExpERT REviEw A Review of Rupatadine in the Treatment of Seasonal Allergic Rhinitis R. Borici-Mazi Medicine and pediatrics, Division of Allergy and immunology,
More informationReview Article Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria
BioMed Research International Volume 2013, Article ID 626837, 6 pages http://dx.doi.org/10.1155/2013/626837 Review Article : A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis
More informationThe Psychomotor Vigilance Test A Measure of Trait or State?
The Psychomotor Vigilance Test A Measure of Trait or State? Hans-Juergen Hoermann, Thomas Uken & Fides-Ronja Voss German Aerospace Center (DLR) Institute of Aerospace Medicine Department of Aviation and
More informationLatest advances in the management of childhood allergic rhinitis
Latest advances in the management of childhood allergic rhinitis Jason Y K Chan Assistant Professor Department of Otorhinolaryngology, Head & Neck Surgery The Chinese University of Hong Kong Disclosures
More informationKey FM scientific principles
Key FM scientific principles Philippa Gander Research Professor, Director Fatigue Management Approaches Symposium 5-6 April 2016, Montréal, Canada Fatigue a physiological state of reduced mental or physical
More informationAllergic Rhinitis. Abstract Allergic rhinitis is defined as an immunologic response moderated by IgE and is. Continuing Education Column
Allergic Rhinitis Hun Jong Dhong, M.D. Department of Otorhinolaryngology Head and Neck Surgery Sungkyunkwan University School of Medicine, Samsung Medical Center E mail : hjdhong@smc.samsung.co.kr Abstract
More information090177e182b31c5d\0.1\Draft\Versioned On:16-Dec :12
MAH: / Product: IBU/PSE Protocol Number EudraCT number (if applicable) Trial report number PMID / D.O.I. (if applicable) Date of trial Is the trial Trial design Background for conducting the trial Participants
More informationEffects of Seasonal Allergic Rhinitis on Driving Ability, Memory Functioning, Sustained Attention, and Quality of Life
The Open Allergy Journal, 2008, 1, 19-25 19 Open Access Effects of Seasonal Allergic Rhinitis on Driving Ability, Memory Functioning, Sustained Attention, and Quality of Life Monique A.J. Mets 1, Edmund
More informationDrug Class Review Newer Antihistamines
Drug Class Review Newer Antihistamines Preliminary Scan Report 1 Update 3 November 2012 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms
More informationAn Update on Allergic Rhinitis. Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital
An Update on Allergic Rhinitis Mike Levin Division of Asthma and Allergy Department of Paediatrics University of Cape Town Red Cross Hospital Allergic Rhinitis Common condition with increasing prevalence
More informationResidual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study
Psychopharmacology (2014) 231:2785 2798 DOI 10.1007/s00213-014-3447-z ORIGINAL INVESTIGATION Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls:
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More informationStudy No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods: Sample Size
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS INTRODUCTION
THE EFFECTS OF THE (SUB)CHRONIC ADMINISTRATION OF AN ANTIHISTAMINE AND MEBHYDROLIN ON REAL CAR DRIVING AND PSYCHOMOTOR PERFORMANCE OF PATIENTS AND HEALTHY VOLUNTEERS * * * * J. J. de Gier, ; J. A. M. Van
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationDefense Technical Information Center Compilation Part Notice
UNCLASSIFIED Defense Technical Information Center Compilation Part Notice ADPO 11043 TITLE: Hr-Antihistamines and Aircrew DISTRIBUTION: Approved for public release, distribution unlimited This paper is
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
More informationCompared with older compounds of this class of drugs, the newer, secondgeneration
Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults Pierre Gehanno, MD*; Clothilde Bremard-Oury, MD ; and Philippe Zeisser, MD Background: Second-generation histamine H 1 -receptor
More informationDoes Exogenous Melatonin Improve Adaptation to Night Shift Work in Residents?
Does Exogenous Melatonin Improve Adaptation to Night Shift Work in Residents? Allegra Grossman A. Study Purpose and Rationale The purpose of this study is to determine whether 3 mg of melatonin ingested
More informationDesloratadine is a second-generation, nonsedating H1-
SYMPOSIUM REPORT SUPPLEMENT Review of Desloratadine Data Using the ARIA Guidelines Elisa Villa, Anthi Rogkakou, Valentina Garelli, and G. Walter Canonica Key Words: seasonal allergy rhinitis, persistent
More informationIMPROVING SAFETY: FATIGUE RISK MANAGEMENT
IMPROVING SAFETY: FATIGUE RISK MANAGEMENT Prof Philippa Gander NZAAA Conference 25/7/2017 Outline What is fatigue? Is fatigue a safety issue in general aviation? Causes of fatigue in general aviation Managing
More informationDrug Class Review. Newer Antihistamines
Drug Class Review Newer Antihistamines Preliminary Scan Report #3 February 2015 Last Report: Update #2, May 2010 The purpose of reports is to make available information regarding the comparative clinical
More informationEffects of Sleep Deprivation on Short Duration Performance Measures Compared to the Wilkinson Auditory Vigilance Task
Sleep, 1(2): 169-176 1978 Raven Press, New York Effects of Sleep Deprivation on Short Duration Performance Measures Compared to the Wilkinson Auditory Vigilance Task Marilyn Glenville, Roger Broughton,
More informationFatigue and Circadian Rhythms
16.400/453J Human Factors Engineering Fatigue and Circadian Rhythms Caroline Lowenthal Lecture 19 1 16.400/453 Outline Situations where fatigue is a factor Effects of fatigue Sleep Components Circadian
More informationSleepiness: Its Measurement and Determinants
Sleep, 5:S128-S134 1982 Raven Press, New York Sleepiness: Its Measurement and Determinants T. Roth, T. Roehrs, and F. Zorick Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, Michigan
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Study Endpoints: Pharmacokinetics:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information1 Report on Sleep Deprivation Trial
In 24, Bowles-Langley Technology, Inc. and Circadian Technology, Inc. conducted a sleep deprivation trial at the Circadian Sleep Lab in Lexington, MA. Funding for this research was from NIOSH. The results
More informationIASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2001) 19:
IASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2001) 19: 171-175 A Double-Blind, Placebo-Controlled, and Randomized Study of Loratadine (Clarityne) Syrup for the Treatment of Allergic Rhinitis in Children
More informationPain Module. Opioid-RelatedRespiratory Depression (ORRD)
Pain Module Opioid-RelatedRespiratory Depression (ORRD) Characteristics of patients who are at higher risk for Opioid- Related Respiratory Depression (ORRD) Sleep apnea or sleep disorder diagnosis : typically
More informationEFFECTS OF BENZODIAZEPINES ON SLEEP AND WAKEFULNESS
Br. J. clin. Pharmac. (1981), 11, 31S-3S EFFECTS OF BENZODIAZEPINES ON SLEEP AND WAKEFULNESS Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, Michigan The differential effects of short
More informationMTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride
MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride COMPOSITION MTnL Tablets Each film-coated tablet contains: Montelukast sodium equivalent to montelukast Levocetirizine dihydrochloride
More informationPERFORMANCE STUDIES WITH ANTIHISTAMINES
Br. J. clin. Pharmnac. (1978), 6,1-5 PERFORMANCE STUDIES WITH ANTIHISTAMINES CORAL H. CLARKE & A.N. NICHOLSON Royal Air Force Institute of Aviation Medicine Farnborough, Hampshire 1 Effect of four antihistamines,
More informationClinical Pharmacology Review for Primary Health Care Providers: I. Antihistamines
TCP 2014;22(1):13-18 http://dx.doi.org/10.12793/tcp.2014.22.1.13 Clinical Pharmacology Review for Primary Health Care Providers: I. Antihistamines Seunghoon Han* Department of Clinical Pharmacology and
More informationClinical Policy: Antihistamines Reference Number: CP.HNMC.18 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal
Clinical Policy: Reference Number: CP.HNMC.18 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationDEXAMPHETAMINE AND ALCOHOL EFFECTS IN SIMULATED DRIVING AND COGNITIVE TASK PERFORMANCE. TNO Human Factors, Soesterberg
DEXAMPHETAMINE AND ALCOHOL EFFECTS IN SIMULATED DRIVING AND COGNITIVE TASK PERFORMANCE Marieke Martens 1, Ries Simons 1, & Jan Ramaekers 2 1 TNO Human Factors, Soesterberg 2 University of Maastricht, Maastricht
More informationSYNOPSIS. A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Phase II Study to Assess the Efficacy and Safety of RHINOCORT
Drug product: RHINOCORT AQUA Drug substance(s): Budesonide Edition No.: Final Study code: D5360C00703 Date: 8 November 2005 SYNOPSIS A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel
More informationComparing the Inhibitory Effects of Diphenhydramine Hydrochloride with Cetirizine Dihydrochloride on Isolated Trachea of Rabbit
ORIGINAL ARTICLE Comparing the Inhibitory Effects of Diphenhydramine Hydrochloride with Cetirizine Dihydrochloride on Isolated Trachea of Rabbit GULSHAN ARA JALBANI 1, MADIHA SHAH 2, MANZOOR AHMED UNAR
More informationEvaluation of Efficacy and Sedative Profiles of H1 Antihistamines by Large-Scale Surveillance Using the Visual Analogue Scale (VAS)
Allergology International. ;57:57-63 DOI:.33allergolint.O-7-55 ORIGINAL ARTICLE Evaluation of Efficacy and Sedative Profiles of H Antihistamines by Large-Scale Surveillance Using the Visual Analogue Scale
More informationAllergic Rhinitis: Effects on Quality of Life and Co-morbid Conditions
Disclosures : Effects on Quality of Life and Co-morbid Conditions Nycomed Pharmaceutical Sepracor Pharmaceutical Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine University of Tennessee
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationAllergic rhinitis is a frequent chronic disease that may. Persistent Allergic Rhinitis and the XPERT Study SYMPOSIUM REPORT SUPPLEMENT
SYMPOSIUM REPORT SUPPLEMENT Persistent Allergic Rhinitis and the XPERT Study Anthi Rogkakou, MD, Elisa Villa, MD, Valentina Garelli, MD, G. Walter Canonica, MD Abstract: Allergic rhinitis (AR) is a chronic
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : FEXOFENADINE Study number : PJPR0024 Study title : A double-blind, randomized, placebo-controlled, parallel study comparing the efficacy and safety of three dosage strengths of MDL 16,455A
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Aerius 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg desloratadine. For a
More informationYour physician has ordered a sleep study for you on. Your arrival time is scheduled for.
Dear Patient: Your physician has ordered a sleep study for you on. Your arrival time is scheduled for. The Texas State Sleep Lab is located in the Health Professions Building on the Texas State University
More informationManagement of Chronic Idiopathic Urticaria
9/3/216 Management of Chronic Idiopathic Urticaria Brian Berman, M.D., Ph.D. Professor Emeritus of Dermatology and Dermatologic Surgery, University of Miami Co-Director Center for Clinical and Cosmetic
More informationFexofenadine s effects, alone and with alcohol, on actual driving and psychomotor performance
Fexofenadine s effects, alone and with alcohol, on actual driving and psychomotor performance Annemiek Vermeeren, MS, and James F. O Hanlon, PhD Maastricht, The Netherlands Background: Fexofenadine is
More informationARIA. At-A-Glance Pocket Reference 2007
ARIA_Glance_2007_8pg:ARIA_Glance_English 9/14/07 3:10 PM Page 1 ARIA At-A-Glance Pocket Reference 2007 1 st Edition NEW ARIA UPDATE BASED ON THE ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA WORKSHOP REPORT
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? THERAPEUTICS
THERAPEUTICS BJD British Journal of Dermatology Night-time sedating H 1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled
More informationSafety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials
Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox, MD San Luis Potosí, Mexico Intranasal mometasone furoate
More informationClinical Trial Results Summary Study EN
Study Number: EN3288-113 Title of Study: A Double-blind, Dose-Ranging, Pilot Study to Evaluate the Safety, Subjective Effects, and Pharmacokinetics of Oxymorphone Hydrochloride in Healthy Subjects Who
More informationThe management of chronic urticaria in primary care for adults and children
The management of chronic urticaria in primary care for adults and children September Version 2.0 This supersedes version 1.0 Review due in September 2019 Document location DOCUMENT CONTROL Copies of this
More informationMorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose
More informationACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST
ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST Investor Webcast July 2016 Copyright The following information contains certain forward-looking statements, relating to the company s business, which can
More informationSupport of Mission and Work Scheduling by a Biomedical Fatigue Model
Support of Mission and Work Scheduling by a Biomedical Fatigue Model Alexander Gundel PhD Karel Marsalek PhD Corinna ten Thoren PhD Institute of Aerospace Medicine, German Aerospace Centre DLR Linder Hoehe,
More informationShift Work, Sleep, Health, Safety, and Solutions. Prof Philippa Gander PhD, FRSNZ Sleep/Wake Research Centre Massey University
Shift Work, Sleep, Health, Safety, and Solutions Prof Philippa Gander PhD, FRSNZ Sleep/Wake Research Centre Massey University Defining shift work Shift work, sleep, health, and safety Shift work and fatigue
More informationComparison of driving performance in treated and untreated Obstructive Sleep Apnoea Syndrome (OSAS) patients and healthy controls
Comparison of driving performance in treated and untreated Obstructive Sleep Apnoea Syndrome (OSAS) patients and healthy controls Dr. Evangelos Bekiaris, Katerina Touliou, Dr. Maria Panou Centre for Research
More informationThe Increasing Importance of Allergies in Asthma Environmental Considerations
The Increasing Importance of Allergies in Asthma Environmental Considerations R. Robert Schellenberg, MD, FRCPC Professor and Head, Division of Allergy and Immunology, UBC Disclosures Medical Advisory
More informationFatigue Risk Management
Fatigue Risk Management Capt. Robert Johnson Senior Pilot, Beijing, China and R. Curtis Graeber, Ph.D. Chief Engineer, Human Factors Chair, ICAO FRM Subteam Boeing Commercial Airplanes 1st ASIA RAST and
More informationIs Afrin (Oxymetazoline) A Safe And Effective Drug In Normal, Healthy Adults With Reference To Nasal Congestion And The Nasal Response?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is Afrin (Oxymetazoline) A Safe And Effective
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationEBAA/ECA Study of Fatigue in Air Taxi, Emergency Medical Service Commercial Air Operations
EBAA/ECA Study of Fatigue in Air Taxi, Emergency Medical Service Commercial Air Operations Presentation to EASA Cologne, 27 th October 2015 Barbara Stone and Mick Spencer FRMSc Limited PO Box 631, Farnham,
More informationF/P F/P VAS. 2 fexofenadine pseudoefedrine F/P F/P F/P. dust mite HDM 17. fexofenadine pseudoefedrine F/P F/P
JJIAO 35 1 : 1 6, 2017 原 著 / 1 1 2 1 1 3 1 2 3 NPO 2 fexofenadine pseudoefedrine F/P F/P 17 12 5 28.6 F/P F/P VAS F/P 8 30 90 8 2 6 8 F/P F/P, fexofenadine/pseudoephedrine; VAS, visual analogue scale 2
More informationPHYSICIAN COMPETENCY FOR ADULT DEEP SEDATION (Ages 14 and older)
Name Score PHYSICIAN COMPETENCY FOR ADULT DEEP SEDATION (Ages 14 and older) 1. Pre-procedure evaluation for moderate sedation should involve all of the following EXCEPT: a) Airway Exam b) Anesthetic history
More informationFatigue and Its Effect on Cabin Crew Member Performance
Wright State University CORE Scholar International Symposium on Aviation Psychology - 2009 International Symposium on Aviation Psychology 2009 Fatigue and Its Effect on Cabin Crew Member Performance Stephanie
More informationA Laboratory Comparison of Clockwise and Counter-Clockwise Rapidly Rotating Shift Schedules, Part I. Sleep
DOT/FAA/AM-02/8 Office of Aerospace Medicine Washington, DC 20591 A Laboratory Comparison of Clockwise and Counter-Clockwise Rapidly Rotating Shift Schedules, Part I. Sleep Crystal Cruz Cristy Detwiler
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More informationSummary of Evidence- Educational & Behavioral Strategies for Children with Disabilities with Sleep Problems 1.
Summary of Evidence- Educational & Behavioral Strategies for Children with Disabilities with Sleep Problems 1. Author, Date Population Design Intervention Results Bartlett & Beaumont 1998 Bramble, 1997
More informationAllergy and inflammation
and inflammation 1 Allergic population hyper-producers of IgE consistently increasing western societies: ~20% of general population 2 Allergic population 3 Allergic triggers 4 Allergic triggers abnormal
More informationWhen are you too tired to be safe?
When are you too tired to be safe? The development of a fatigue index tool Andrew Kilner EUROCONTROL The European Organisation for the Safety of Air Navigation Motivation Developing a fatigue index for
More informationPhototherapy in Allergic Rhinitis
Phototherapy in Allergic Rhinitis Rhinology Chair KSU KAUH Ibrahim AlAwadh 18\1\2017 MBBS, SB & KSUF Resident, ORL-H&N Background: Endonasal phototherapy can relieve the symptoms of allergic rhinitis
More informationA review of the effects of antihistamines on mental processes related to automobile driving
A review of the effects of antihistamines on mental processes related to automobile driving F. M. Gengo, PharmD, ac and C. Manning a Buffalo, N.Y. The newer, second-generation Hi-receptor antagonists have
More informationT. Roth, Ph.D., T. Roehrs, Ph.D., G. Koshorek, J. Sicldost^, B.A., and
T. Roth, Ph.D., T. Roehrs, Ph.D., G. Koshorek, J. Sicldost^, B.A., and F. Zorick, M.D. Detroit, Mich. The central effects of a newly developed, long-acting H, antihistamine, loratadine (10 and ), were
More informationEFFICACY AND SAFETY OF OLOPATADINE/MOMETASONE COMBINATION NASAL SPRAY FOR THE TREATMENT OF SEASONAL ALLERGIC RHINITIS
EFFICACY AND SAFETY OF OLOPATADINE/MOMETASONE COMBINATION NASAL SPRAY FOR THE TREATMENT OF SEASONAL ALLERGIC RHINITIS PAUL H. RATNER 1 ; FRANK HAMPEL 2 ; AURORA BREAZNA 3 ; CYNTHIA F. CARACTA 3 ; SUDEESH
More information